52 completed, 6 not yet recruiting, 4 terminated, 4 unknown. 27 Phase 1, 16 Phase 2, 7 Phase 4, 5 Not applicable, 2 Phase 3.
Follow Bacillaceae Infections: new trials by email Literature Review of Bacillaceae Infections trials Research Report on Bacillaceae Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Prophylaxis of Anthrax Disease. CYFENDUS - Anthrax | Not yet recruiting | Emergent BioSolutions | 250 | 2035-11-01 | 2025-12-08 | |
| A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax Patients AIGIV - Inhalational Anthrax | Not yet recruiting | Emergent BioSolutions | 100 | 2027-05-30 | 2026-02-06 | |
| Observational Study of Raxibacumab in Sporadic Cases of Systemic Anthrax Collection of samples - Infections, Bacterial | Not yet recruiting | Emergent BioSolutions | 10 | 2027-05-01 | 2026-03-17 | |
| Clinical Benefit and Safety of Raxibacumab in Patients With Symptomatic Inhalational Anthrax in a Mass Exposure Scenario Sample Collection - Infections, Bacterial | Phase 4 | Not yet recruiting | Emergent BioSolutions | 100 | 2027-01-01 | 2026-02-06 |
| Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Anthrax AIGIV - Anthrax | Not yet recruiting | Emergent BioSolutions | 10 | 2026-11-30 | 2026-02-06 | |
| Combined Gastrointestinal Decontamination in Acute Severe Poisoning Combination of activated charcoal with polyethylene glycol for digestive decontamination, Standard Treatment (Guideline-Based) - Severe Poisoning With Cardiotropic or Psychotropic Drug, Admission to Intensive Care | Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 200 | 2026-06-24 | 2026-07-06 |
| Cigarette Filter Study Charcoal filtered cigarettes with marketing, Charcoal filtered cigarette without marketing, Non-charcoal filtered cigarettes - Smoking ( Cigarette) | Not applicable | Recruiting | Rutgers, The State University of New Jersey | 252 | 2026-04-27 | 2026-06-05 |
| SGLT2 Inhibitor Utilization Re-perfusion Therapy Canagliflozin 100mg - Acute Ischemic Stroke From Large Vessel Occlusion | Phase 4 | Not yet recruiting | Taichung Veterans General Hospital | 150 | 2026-04-13 | 2026-04-03 |
| Comparative Clinical Assessment of Charcoal and Conventional Toothbrushes charcoal toothbrush - Dental Plaque | Not applicable | Completed | Cairo University | 36 | 2026-01-01 | 2026-05-04 |
| Effect of Activated Charcoal on Serum Osmolality, Osmolal Gap, and Enzymatic Ethylene Glycol Assay Activated Charcoal - Osmolality Disturbance, Lab Interference | Active not recruiting | State University of New York - Upstate Medical University | 8 | 2025-11-15 | 2026-07-31 | |
| Activated CHARcoal in Poisoned Patient - Pilot Trial Activated Charcoal, No activated charcoal - Charcoal, Decontamination, Poisoning | Phase 4 | Recruiting | Laval University | 100 | 2025-07-16 | 2026-01-29 |
| The Effect of Probiotics vs Activated Charcoal in the Management of CKD Patients Suffering From Uremic Pruritus. Probiotic Blend Capsule, Activated Charcoal - Chronic Kidney Disease, Uremic Pruritus | Phase 2 | Unknown | Ain Shams University | 123 | 2024-09-01 | 2024-08-30 |
| The Effect of AC-134 in Chronic Kidney Diseases Low protein diet with AC-134, Standard treatment - Nephrology | Not applicable | Completed | Taichung Veterans General Hospital | 100 | 2024-06-05 | 2026-06-12 |
| A Case-control Study on the Clinical Characteristics of 28-day and 90-day Death From Severe Anthrax Anthrax | Unknown | Qin Ning | 80 | 2024-03-13 | 2024-04-15 | |
| Anthrax AV7909 Boost Evaluation Study AV7909 Full Dose (0.5 mL), AV7909 Half Dose (0.25 mL), Placebo: Sodium Chloride Injection, USP 0.9% (0.5 mL) - Anthrax | Phase 2 | Completed | Biomedical Advanced Research and Development Authority | 220 | 2023-12-05 | 2026-10-20 |
| An Open Label Field Study of Anthim (Obiltoxaximab) in Subjects Exposed to B. Anthracis Collection of samples, Obiltoxaximab - Infection, Bacterial, Anthrax | Phase 4 | Unknown | Elusys Therapeutics | 100 | 2023-12-01 | 2023-07-14 |
| Evaluation of the SRI B. Anthracis Lethal Factor Diagnostic System Anthrax LF Dx System - Anthrax | Terminated | SRI International | 343 | 2023-01-23 | 2023-11-30 | |
| Anthrax AV7909 Liquid vs Lyophilized AV7909 - Anthrax, Anthrax Immunisation | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 41 | 2022-05-25 | 2024-12-19 |
| A Study to Evaluate the Effect of Activated Charcoal With Sorbitol on the Single-dose of Mavacamten in Healthy Participants Mavacamten, Activated Charcoal with Sorbitol - Healthy Participants | Phase 1 | Completed | Bristol-Myers Squibb | 45 | 2022-04-15 | 2022-11-08 |
| Charcoal in Lung Cancer Patients Undergoing TEMLA Activated charcoal - Lung Cancer | Phase 2 | Withdrawn | Masonic Cancer Center, University of Minnesota | 2022-01-26 | 2022-02-09 |
Showing 20 of 73. Sign in to see all of them.
Anthrax (73) · Bacterial Infections (6) · Infections (4) · Inhalation anthrax (4) · Poisoning (4) · Cholangitis (2) · Cholecystitis (2) · Peritonitis (2) · Pneumonia (2) · Renal Insufficiency, Chronic (2) · Sepsis (2) · Anemia (1) · Asthma (1) · Breast Neoplasms (1)
Bacterial Infections and Mycoses (73) · Gram-Positive Bacterial Infections (72) · Infections (69) · Bacterial Infections (67) · Chemically-Induced Disorders (5) · Lung Diseases (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Respiratory Tract Diseases (5) · Urogenital Diseases (4) · Chronic Disease (3) · Digestive System Diseases (3) · Disease Attributes (3) · Female Urogenital Diseases (3)
Charcoal (12) · Biothrax (11) · Anthrax Vaccines (8) · Ciprofloxacin (7) · Sodium Chloride (5) · obiltoxaximab (5) · Anthrax Immune Globulin Intravenous (3) · Injections (3) · Doxycycline (2) · Metered Dose Inhalers (2) · Replication Protein A (2) · Rivaroxaban (2) · AVP-21D9 (1) · Amodiaquine (1) · Artesunate (1)
Emergent BioSolutions (14) · National Institute of Allergy and Infectious Diseases (NIAID) (7) · Elusys Therapeutics (4) · Bayer (3) · PharmAthene, Inc. (3) · Altimmune, Inc. (2) · Biomedical Advanced Research and Development Authority (2) · Centre Hospitalier Universitaire de Saint Etienne (2) · Masonic Cancer Center, University of Minnesota (2) · PharmAthene UK Limited (2) · Taichung Veterans General Hospital (2) · Ain Shams University (1) · Assistance Publique - Hôpitaux de Paris (1) · AstraZeneca (1) · BlueWillow Biologics (1)
United States (46) · France (4) · Japan (3) · South Korea (2) · United Kingdom (2) · Canada (1) · China (1) · Egypt (1) · Mali (1) · Switzerland (1) · Taiwan (1)
Bojan Drobic, PhD (2) · Brandon Essink, MD (2) · Robert Hopkins, MD, MPH, TM (2) · Alex King, MD (1) · Aliaa Mohamed (1) · Antonio Rusca, MD, FMH (1) · Armin J Rashidi, MD, PhD (1) · Armin Rashidi, MD, PhD (1) · Barbara K Lomeli, M.D. (1) · Bojan Drobic (1) · Carlos Fierro, MD (1)
PMID 27568215, PMID 14517111, PMID 14647116, PMID 15069910, PMID 15635137, PMID 21079762, PMID 21368772, PMID 21615456, PMID 23701746, PMID 23741398, PMID 23979731, PMID 24373307, PMID 24733473, PMID 26865594, PMID 27567243, PMID 27910037, PMID 29789393, PMID 30446594, PMID 31537189, PMID 31787498, PMID 33129609, PMID 34544599, PMID 35153091, PMID 38352727, PMID 38926266, PMID 41401704, PMID 41447782
2015 (1), 2016 (1), 2019 (1), P01CA190193 (1), R37CA296976 (1), UL1TR002494 (1)